Top Clinical Trials companies in Netherlands by Price to Earnings Ratio (P/E)

This ranking features the top 7 Clinical Trials companies in Netherlands ranked by Price to Earnings Ratio (P/E), averaging a Price to Earnings Ratio (P/E) of 9.87, for July 03, 2025.

#	Name	Market Capitalization Share Price Year-To-Date (YTD) return Revenue Revenue Year-on-Year (YoY) growth Operating Income EBIT EBITDA Free Cash Flow Dividend Yield Free Cash Flow Yield Total Assets Total Liabilities Cash and Short-Term Investments	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

Frequently Asked Questions

Which Clinical Trials company in Netherlands has the highest Price to Earnings Ratio (P/E) ?

The Clinical Trials company in Netherlands with the highest Price to Earnings Ratio (P/E) is Qiagen N.V. (NYSE: QGEN) at 112.44.

Which Clinical Trials company in Netherlands has the lowest Price to Earnings Ratio (P/E) ?

The Clinical Trials company in Netherlands with the lowest Price to Earnings Ratio (P/E) is Merus N.V. (NasdaqGM: MRUS) at -14.32.

What are the top 10 Clinical Trials companies in Netherlands by Price to Earnings Ratio (P/E) ?

The top 10 Clinical Trials companies in Netherlands by Price to Earnings Ratio (P/E) are Qiagen N.V., LAVA Therapeutics N.V., uniQure N.V., Pharvaris N.V., ProQR Therapeutics N.V., NewAmsterdam Pharma Company N.V. and Merus N.V..

What are the bottom 10 Clinical Trials companies in Netherlands by Price to Earnings Ratio (P/E) ?

The bottom 10 Clinical Trials companies in Netherlands by Price to Earnings Ratio (P/E) are Merus N.V., NewAmsterdam Pharma Company N.V., ProQR Therapeutics N.V., Pharvaris N.V., uniQure N.V., LAVA Therapeutics N.V. and Qiagen N.V..